open access
The patient with 5q minus syndrome and V617F mutation with the presence of ringed erythroblasts meeting the criteria of RARS-T effectively treated with lenalidomide – A case report
Affiliations- University Hospital No. 2 – Biziel Memorial Hospital, Bydgoszcz, Poland
- Department of Radiology and Diagnostic Imaging, Nicolaus Copernicus University, Collegium Medicum, Bydgoszcz, Poland
- Medical University of Gdansk, Department of Clinical Chemistry and Biochemistry, Gdansk, Poland
- Department of Diagnostic Hematology, Institute of Hematology and Transfusion Medicine, Warsaw, Poland
open access
Abstract
5q minus syndrome is a form of myelodysplastic syndrome characterized by the presence of an isolated deletion of long arm of the chromosome 5. Patients with 5q minus respond well to the treatment with lenalidomide. The presence of the JAK2 V617F mutation is a common feature of refractory anemia with ring sideroblasts and marked thrombocytosis. Much less is known about effectiveness of lenalidomide in these patients. We present the patient with 5q minus syndrome and JAK2 V617F mutation accompanied by the presence of ringed erythroblasts meeting the criteria of RARS-T. We could identify only two such patients reported in the literature; no details were given about effectiveness of lenalidomide in that group. We observed good response to the treatment with lenalidomide with transfusion independence 9 months after starting of the treatment; however, there was no complete eradication of del (5)(q13q31) clone nor the clone with JAK V617F mutation.
Abstract
5q minus syndrome is a form of myelodysplastic syndrome characterized by the presence of an isolated deletion of long arm of the chromosome 5. Patients with 5q minus respond well to the treatment with lenalidomide. The presence of the JAK2 V617F mutation is a common feature of refractory anemia with ring sideroblasts and marked thrombocytosis. Much less is known about effectiveness of lenalidomide in these patients. We present the patient with 5q minus syndrome and JAK2 V617F mutation accompanied by the presence of ringed erythroblasts meeting the criteria of RARS-T. We could identify only two such patients reported in the literature; no details were given about effectiveness of lenalidomide in that group. We observed good response to the treatment with lenalidomide with transfusion independence 9 months after starting of the treatment; however, there was no complete eradication of del (5)(q13q31) clone nor the clone with JAK V617F mutation.
Keywords
5q minus; JAK2 V617F mutation; RARS-T; MDS; Lenalidomide
About this articleTitle
The patient with 5q minus syndrome and V617F mutation with the presence of ringed erythroblasts meeting the criteria of RARS-T effectively treated with lenalidomide – A case report
Journal
Issue
Pages
29-32
Published online
2016-01-01
Page views
103
Article views/downloads
108
DOI
10.1016/j.achaem.2015.12.002
Bibliographic record
Acta Haematol Pol 2016;47(1):29-32.
Keywords
5q minus
JAK2 V617F mutation
RARS-T
MDS
Lenalidomide
Authors
Marcin Kruszewski
Adriana Czyż
Krzysztof Lewandowski
Monika Prochorec-Sobieszek
Jarosław Czyż